Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
about
Management of people with early or very early stage hepatocellular carcinoma: a network meta-analysisManagement of people with intermediate-stage hepatocellular carcinoma: a network meta-analysisThe significance of genetics for cholangiocarcinoma developmentCholangiocarcinoma: Current Knowledge and New DevelopmentsSystemic Therapy of Cholangiocarcinoma.Raf kinase inhibitor protein inhibits cholangiocarcinoma cell metastasis by downregulating matrix metalloproteinase 9 and upregulating tissue inhibitor of metalloproteinase 4 expression.Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1.Capsaicin treatment attenuates cholangiocarcinoma carcinogenesisMultidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.PIK3CA mutation detection in metastatic biliary cancer using cell-free DNAAntitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.New insights into the molecular pathogenesis of intrahepatic cholangiocarcinomaMolecular pathogenesis of intrahepatic cholangiocarcinoma.Cholangiocellular Carcinoma.Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma.Epidemiology and Risk Factors of Cholangiocarcinoma.Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma.Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibitionAntitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cellsTime and deprivation trends in incidence of primary liver cancer subtypes in England.Adjuvant treatment in biliary tract cancer: to treat or not to treat?Systematic underreporting of the population-based incidence of pancreatic and biliary tract cancers.A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe.Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system.Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.Identification of prognostic factors and the impact of palliative resection on survival of patients with stage IV hepatolithiasis-associated intrahepatic cholangiocarcinoma.Incidence and mortality trends for biliary tract cancers in Austria.Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.Therapie des metastasierten Cholangiokarzinoms
P2860
Q24186856-14341E9C-344A-42B3-B967-F81306C8D185Q24186892-7C93AC79-DB82-4D7C-A763-54ECAABBEC5CQ26865749-8A101294-D497-4F94-A8FC-295E0E091045Q28076098-3D89C7AE-BB1B-4414-A24C-CD1005FA0C74Q34551877-2F14F8EA-68DA-4366-933D-23649854BE93Q34582601-87A806E4-2C07-494B-8ADA-9BE509C16949Q34681207-A1A212AD-228E-4787-8701-79D29F5394E7Q35035238-72F285FA-53ED-4547-83A2-7130C8F1461AQ35151115-C51AF381-BA63-441B-B86F-0F13488819C9Q35153098-1E782C79-A7BE-4FBE-A5B7-9D513FC862A5Q35674607-2F306246-9C4F-43E6-870B-ACDC98167B10Q35913384-63FB4BDC-492C-4542-9D92-F138892471C2Q36545534-D3D84B46-C662-4793-B469-5C2FFEC7FF20Q37190258-CB38136B-7B78-4CDD-BC4D-A467D7604B28Q37621790-85FEFA16-1D85-41D0-A8E9-D06EC91E770BQ38244965-8265CFA7-08FB-47E2-B321-173CAC4C9305Q38746546-0B1C9B0E-DDDB-439B-8407-D1229803325CQ38747707-532E6473-04C5-484B-A5CC-E9AC93DF3D39Q39022105-73E65B89-9248-44BC-8666-2A4B05AF8928Q39147308-11ED8C9D-7059-417E-9482-2D401EAAE8C5Q39240982-3C53ACDC-4914-4BD8-A0B4-1F6A5E8170C3Q41083899-8B29EB99-DD54-4554-B1C6-E8041E8CF0D9Q41670809-EA09E912-32F3-46D9-AB1A-61ED3B17ABFBQ42199556-8721101F-89C2-47C7-A415-4600B7532F83Q42214199-515B43FB-26C9-41F6-8E79-884D437BACEAQ43193059-63DD4A1D-6AF1-46C5-9493-96CDB95ADC57Q44693983-0E0FAA52-7C48-47B0-B023-322264D8B84DQ45045994-443F28C2-BE00-408A-A2E4-3B8FE6EC1715Q47576786-C3901F19-B420-4C7D-8301-1CABE7D0069BQ47955863-384B9C1A-1C0A-432F-8BAA-8962FE24084BQ54483923-AA0A3395-E584-43B4-B5E4-9850D978C372Q54774218-86C9207F-E563-4B4C-A578-657531097458Q55032209-F9AE06A5-58A6-4D15-8A03-4C344E659D35Q57074642-A1D1B5E0-D0D0-42C3-A460-48DF393BD020
P2860
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
@en
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
@nl
type
label
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
@en
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
@nl
prefLabel
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
@en
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
@nl
P2093
P2860
P1476
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany
@en
P2093
Gerd Wegener
Heiner Wedemeyer
Michael P Manns
Nisar P Malek
Ruben R Plentz
Sandra Ciesek
Thomas von Hahn
Tim F Greten
P2860
P304
P356
10.3109/00365521.2011.589472
P577
2011-06-22T00:00:00Z